Furthermore, CRISPR/Cas9-mediated knockout of the DGK, as a possible regulator of TGF-β, boosts the anti-tumor activity of the CAR-T versus U87MGvIII glioblastoma cell in vitro and murine models mainly by the triggering resistance to TGF-β and also PGE2 [9]. Here, TGFB1 is linked to glioblastoma.